Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24629160 | 0.81 | ALDH1A1 (0.52) | HSD17B10NOS1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25903530 | 0.78 | NOS1 (0.47) | HSD17B10NOS1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25899101 | 0.78 | HSD17B10 (0.71) | HSD17B10NOS1ALDH1A1HPGDKDM4E | |
| SCHEMBL6363552 | 0.71 | HSD17B10 (0.52) | HSD17B10NOS1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL25899165 | 0.71 | ALDH1A1 (0.49) | HSD17B10ALDH1A1HPGDSMN1; SMN2KDM5B | |
| SCHEMBL9196608 | 0.70 | AKR1B1 (0.40) | HCAR2KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL25899167 | 0.69 | HSD17B10 (0.32) | HSD17B10 | |
| SCHEMBL6363202 | 0.69 | HSD17B10 (0.49) | HSD17B10NOS1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL59519 | 0.69 | HSD17B10 (0.69) | HSD17B10NOS1ALDH1A1HPGDKDM4E | |
| SCHEMBL59520 | 0.69 | HSD17B10 (0.69) | HSD17B10NOS1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | HSD17B10 4659/4885NOS1 4318/4885ALDH1A1 4520/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | HSD17B10 4755/4885NOS1 4179/4885ALDH1A1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.